---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-111528"
form_type: "8-K"
ticker: "OPRX"
cik: "0001448431"
company_name: "OptimizeRx Corp"
filed_at: "2024-12-23T23:59:59+00:00"
generated_at: "2026-05-28T23:34:33.342876+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# OptimizeRx CEO William Febbo to step down Dec 31; President Stephen Silvestro named interim CEO

## Summary
- CEO William Febbo departs effective Dec 31, 2024; will provide advisory services through March 2025.
- Board appoints President Stephen Silvestro as interim CEO; search for permanent CEO initiated.
- Company reaffirms FY2024 guidance; expects revenue and adjusted EBITDA at higher end of range.
- Febbo had been CEO for nearly nine years; board expresses gratitude and confidence in team.
- Silvestro joined OptimizeRx in 2019, became President in October 2023; previously Chief Commercial Officer.

## SEC filing metadata
- accession: 0001213900-24-111528
- form_type: 8-K
- ticker: OPRX
- cik: 0001448431
- company_name: OptimizeRx Corp
- filed_at: 2024-12-23T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1448431/000121390024111528/0001213900-24-111528-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1448431/000121390024111528/ea0225680-8k_optimize.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-111528
- JSON: https://secwatch.observer/filing/0001213900-24-111528.json
- Plain text: https://secwatch.observer/filing/0001213900-24-111528.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.